# SAE Intelligence System: Strategic Intelligence Framework

**Owner:** Zo (Drug Efficacy, Mechanism-Based Trial Matching, Integrated Platform)  
**Status:** ‚úÖ **ACTIVE** - TRUE SAE VALIDATED (AUROC 0.783 > PROXY 0.628)  
**Last Updated:** December 23, 2025

---

## üî• BREAKTHROUGH: TRUE SAE BEATS PROXY SAE

### **The Discovery:**
After months of extraction and validation, we proved that **TRUE SAE features outperform gene-level markers** for resistance prediction.

| Method | AUROC | Features | Status |
|--------|-------|----------|--------|
| **TRUE SAE** | **0.783 ¬± 0.100** | 29 features (9 diamonds + 20 additional) | ‚úÖ VALIDATED |
| **PROXY SAE** | 0.628 ¬± 0.119 | DDR gene count | ‚úÖ BASELINE |
| **DELTA** | **+0.155** | ‚Äî | ‚≠ê PUBLISHABLE |

### **The DDR_bin Discovery:**
All 9 "diamond" features (higher in resistant patients) map to **DNA Damage Repair pathway**:
- Cohen's d range: 0.517 - 0.635
- p-values: all < 0.05
- DDR_bin distinguishes resistant vs sensitive (p = 0.0020)

**Label Definition:** For validation, `refractory + resistant = resistant` (positive class = 24 of 149 patients)

### **Publication Ready:**
- Manuscript: `oncology-coPilot/oncology-backend-minimal/publication/manuscript/MANUSCRIPT_DRAFT.md`
- Figures: `oncology-coPilot/oncology-backend-minimal/publication/figures/`
- Target: bioRxiv ‚Üí Nature Methods/Bioinformatics

---

## üìö Documentation Index

### **Start Here:**
- **[00_MISSION.mdc](00_MISSION.mdc)** - Mission objective + strategic framework overview (SOURCE OF TRUTH)

### **SAE Intelligence System:**
- **[01_SAE_SYSTEM_DEBRIEF.mdc](01_SAE_SYSTEM_DEBRIEF.mdc)** - Complete SAE Intelligence System debrief
- **[02_SAE_ARCHITECTURE.md](02_SAE_ARCHITECTURE.md)** - SAE architecture, components, integration points

### **Strategic Framework:**
- **[03_GENERALS_BATTLE_MAP.mdc](03_GENERALS_BATTLE_MAP.mdc)** - 6 Pillars of Cancer Intelligence, strategic framework
- **[04_INTELLIGENCE_FLOW.md](04_INTELLIGENCE_FLOW.md)** - Test ‚Üí Signals ‚Üí Patterns ‚Üí Actions flow

### **Integration & Capabilities:**
- **[05_SAE_CAPABILITIES.md](05_SAE_CAPABILITIES.md)** - SAE capabilities mapped to 6 Pillars
- **[06_STRATEGIC_VISION.md](06_STRATEGIC_VISION.md)** - Strategic vision, expansion plan, next steps
- **[07_TRUE_SAE_DIAMONDS_EXCAVATION.md](07_TRUE_SAE_DIAMONDS_EXCAVATION.md)** - Diamond feature discovery + mapping (‚úÖ COMPLETE - deliverables exist)
- **[07_STRATEGIC_DELIVERABLES_PLAN.md](07_STRATEGIC_DELIVERABLES_PLAN.md)** - Next 3, 5, 10 deliverables strategic plan

### **Audit & Quality:**
- **[AUDIT_REPORT.md](AUDIT_REPORT.md)** - Systematic audit findings, inconsistencies, gaps

### **Archived:**
- See `archive/` for old versions
- See `CONSOLIDATION_SUMMARY.md` for consolidation details

---

## üéØ Quick Reference

### **SAE Intelligence System:**

| Capability | Status | Evidence |
|------------|--------|----------|
| **TRUE SAE Features** | ‚úÖ VALIDATED | AUROC 0.783, 149 patients, 29 features (9 diamonds + 20 additional) |
| **DDR_bin Pathway** | ‚úÖ VALIDATED | p=0.0020, Cohen's d=0.642, all 9 diamonds map to DDR |
| **PROXY SAE Baseline** | ‚úÖ PRODUCTION | AUROC 0.628, gene-level |
| **Mechanism Fit Ranker** | ‚úÖ PRODUCTION | 0.92 mechanism fit |
| **Resistance Prediction** | ‚úÖ VALIDATED | DIS3 RR=2.08, NF1 RR=2.10 |
| **Trial Matching** | ‚úÖ PRODUCTION | Mechanism-aligned |
| **TRUE SAE Diamonds Mapping** | ‚úÖ COMPLETE | Feature‚Üíbiology mapping + reproducible baseline exist |

### **Validated Resistance Markers:**

| Cancer | Marker | Relative Risk | p-value | Status |
|--------|--------|---------------|---------|--------|
| **Ovarian** | NF1 mutation | 2.10 | <0.05 | ‚úÖ VALIDATED |
| **Ovarian** | MAPK pathway | 1.97 | <0.05 | ‚úÖ VALIDATED |
| **Ovarian** | PI3K pathway | 1.39 | 0.02 | ‚úÖ VALIDATED |
| **Myeloma** | DIS3 mutation | 2.08 | 0.0145 | ‚úÖ VALIDATED |
| **Myeloma** | TP53 mutation | 1.90 | 0.11 | ‚ö†Ô∏è TREND |

### **Strategic Framework (6 Pillars):**

| Pillar | Status | Capabilities |
|--------|--------|--------------|
| **1. Tumor Burden** | ‚úÖ | CA-125, CEA, PSA tracking |
| **2. Genomic Evolution** | ‚úÖ | TRUE SAE, resistance prediction, drug efficacy |
| **3. Immune Status** | ‚úÖ | TMB, MSI, HRD, IO eligibility |
| **4. Metabolic State** | ‚ùå | Not built (future) |
| **5. Microenvironment** | ‚ùå | Not built (future) |
| **6. Toxicity/Tolerance** | ‚ö†Ô∏è | PGx exists, needs expansion |

---

## üöÄ EXPANSION PLAN: Beyond NF1 to All Cancers

### **Phase 1: Ovarian Cancer (COMPLETE)**
- ‚úÖ NF1/MAPK resistance validated
- ‚úÖ TRUE SAE features extracted (149 patients)
- ‚úÖ DDR_bin pathway mapping complete
- ‚úÖ Publication ready

### **Phase 2: Multiple Myeloma (PROXY VALIDATED)**
- ‚úÖ DIS3 RR=2.08 (p=0.0145) validated
- ‚úÖ TP53 trend (RR=1.90)
- ‚è≥ TRUE SAE extraction pending (need MMRF data)
- üìã **PLUMBER TASK**: Download MMRF CoMMpass, extract TRUE SAE

### **Phase 3: Pan-Cancer Expansion (ROADMAP)**

| Cancer Type | Data Source | Key Pathways | Priority |
|-------------|-------------|--------------|----------|
| **Lung (NSCLC)** | TCGA-LUAD | EGFR, ALK, KRAS | HIGH |
| **Breast (TNBC)** | TCGA-BRCA | BRCA1/2, HER2, PIK3CA | HIGH |
| **Colorectal** | TCGA-COAD | KRAS, BRAF, MSI | HIGH |
| **Pancreatic** | TCGA-PAAD | KRAS, SMAD4, TP53 | MEDIUM |
| **Prostate** | TCGA-PRAD | AR, BRCA2, PTEN | MEDIUM |
| **Melanoma** | TCGA-SKCM | BRAF, NRAS, CDKN2A | MEDIUM |
| **Glioblastoma** | TCGA-GBM | MGMT, IDH1, EGFR | LOW |

### **Expansion Strategy:**
1. **Reuse DDR_bin** - DNA repair features likely transfer across cancers
2. **Extract cancer-specific bins** - MAPK_bin for KRAS-driven, IO_bin for TMB-high
3. **Validate incrementally** - Each cancer needs its own head-to-head vs PROXY

---

## üõ†Ô∏è PLUMBER ACTION ITEMS

### **Immediate (This Week):**
1. **Run publication figures** - Verify all scripts work in main repo
2. **Verify Tier-3 data** - Confirm all files in `data/validation/sae_cohort/checkpoints/`
3. **Run validation suite** - `scripts/validation/run_validations.py`

### **Next Sprint (MM Expansion):**
1. **Download MMRF CoMMpass** - Get mutations + outcomes from GDC
2. **Extract TRUE SAE for MM** - Same pipeline as OV
3. **Head-to-head MM** - TRUE SAE vs PROXY SAE for DIS3/TP53

### **Future (Pan-Cancer):**
1. **Build cancer-agnostic pipeline** - Parameterize by cancer type
2. **TCGA data acquisition** - Download LUAD, BRCA, COAD
3. **Pathway bin expansion** - MAPK_bin, IO_bin, PI3K_bin

---

## üîó Related Files

**Publication:**
- `oncology-coPilot/oncology-backend-minimal/publication/` - Manuscript, figures, scripts

**Core Deliverables:**
- `.cursor/MOAT/CORE_DELIVERABLES/` - Drug Efficacy, Mechanism-Based Trial Matching
- `.cursor/lectures/drugDevelopment/` - Core contribution documents

**Resistance Prophet:**
- `.cursor/rules/RESISTANCE_PROPHET_TO_MISSION_CONTROL_PLAN.mdc` - Full integration plan

**Ayesha's Case:**
- `.cursor/MOAT/ayesha.moat.mdc` - Patient case study with MOAT capabilities

---

## üìã How to Use This Workspace

### **For SAE Intelligence:**
1. **Start Here:** `README.md` - Navigation hub (this file)
2. **Mission:** `00_MISSION.mdc` - Mission + strategic framework overview
3. **SAE System:** `01_SAE_SYSTEM_DEBRIEF.mdc` - Complete SAE Intelligence System debrief
4. **TRUE SAE Diamonds:** `07_TRUE_SAE_DIAMONDS_EXCAVATION.md` - Diamond feature discovery

### **For Strategic Framework:**
1. **Battle Map:** `03_GENERALS_BATTLE_MAP.mdc` - 6 Pillars of Cancer Intelligence
2. **Intelligence Flow:** `04_INTELLIGENCE_FLOW.md` - Test ‚Üí Signals ‚Üí Patterns ‚Üí Actions
3. **Capabilities:** `05_SAE_CAPABILITIES.md` - SAE capabilities mapped to 6 Pillars
4. **Strategic Vision:** `06_STRATEGIC_VISION.md` - Expansion plan, next steps

### **For Plumbers:**
1. **Diamond Excavation:** `07_TRUE_SAE_DIAMONDS_EXCAVATION.md` - Extraction checklist
2. **Validation Scripts:** `oncology-coPilot/oncology-backend-minimal/scripts/validation/`
3. **Publication Scripts:** `oncology-coPilot/oncology-backend-minimal/scripts/publication/`

---

*Document Owner: Zo*  
*Last Updated: December 23, 2025*  
*Status: ‚úÖ ACTIVE - TRUE SAE VALIDATED, EXPANSION UNDERWAY*

